Prostate cancer Archives

Two eye-catching research projects involving drugs from Roche have produced disappointing trial results, after its prostate cancer drug

Mixed results for Roche drugs in prostate cancer and COVID-19

https://pharmaphorum.com/news/mixed-results-for-roche-drugs-in-prostate-cancer-and-covid-19/

News/ News/ Oncology/ Top stories

AZ/Merck & Co take on Clovis as FDA approves prostate cancer drug

Richard Staines AstraZeneca, cancer, Clovis, Merck & Co, Oncology, Prostate cancer 0 Comment

The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator

AZ/Merck & Co take on Clovis as FDA approves prostate cancer drug

https://pharmaphorum.com/news/az-merck-cos-lynparza/

News/ News/ Oncology

Clovis steals march on AZ with PARP prostate approval

Richard Staines AstraZeneca, cancer, Clovis, Prostate cancer, Rubraca 0 Comment

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP

Clovis steals march on AZ with PARP prostate approval

https://pharmaphorum.com/news/clovis-steals-march-on-az-with-parp-prostate-approval/

News/ News/ Oncology

Xtandi takes fight to prostate cancer rivals with survival data

Phil Taylor Astellas, Oncology, Pfizer, Prostate cancer, Xtandi 0 Comment

Pfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend

Xtandi takes fight to prostate cancer rivals with survival data

https://pharmaphorum.com/news/xtandi-takes-fight-to-prostate-cancer-rivals-with-survival-data/

News/ News/ Oncology

AZ and MSD’s Lynparza gets fast prostate cancer FDA review

Richard Staines AstraZeneca, cancer, Clovis, Prostate cancer 0 Comment

The FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the

AZ and MSD’s Lynparza gets fast prostate cancer FDA review

https://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/

News/ News/ Oncology

Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca

Richard Staines cancer, Clovis, Prostate cancer 0 Comment

The FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate

Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca

https://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/

News

AZ sells ex-US rights to old cancer drugs Arimidex and Casodex

Richard Staines AstraZeneca, breast cancer, cancer, Prostate cancer 0 Comment

For several years AstraZeneca has been selling off rights to its older drugs to raise cash as it

AZ sells ex-US rights to old cancer drugs Arimidex and Casodex

https://pharmaphorum.com/news/az-sells-ex-us-rights-to-old-cancer-drugs-arimidex-and-casodex/

News/ News/ Oncology

Xtandi catches up with Erleada in castration-sensitive prostate cancer

Phil Taylor Astellas, Erleada, Oncology, Pfizer, Prostate cancer, Xtandi 0 Comment

Pfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a

Xtandi catches up with Erleada in castration-sensitive prostate cancer

https://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/

News/ News/ Oncology

Merck & Co’s Keytruda shows promise with prostate cancer ‘super responders’

Richard Staines cancer, Merck & Co, Prostate cancer 0 Comment

A small proportion of men with advanced prostate cancer, who have exhausted all other treatment options, were ‘super

Merck & Co’s Keytruda shows promise with prostate cancer ‘super responders’

https://pharmaphorum.com/news/merck-cos-keytruda-shows-promise-with-prostate-cancer-super-responders/

Trending

Prostate cancer

Login